Active Ingredient History
Hemin (trade name Panhematin) is a protoporphyrin IX containing a ferric iron ion (heme B) with a chloride ligand, which is is indicated for the amelioration of recurrent attacks of acute intermittent porphyria temporally related to the menstrual cycle in susceptible women. Manifestations such as pain, hypertension, tachycardia, abnormal mental status and mild to progressive neurologic signs may be controlled in selected patients with this disorder. the therapy for the acute porphyrias is not curative. Heme acts to limit the hepatic and/or marrow synthesis of porphyrin. This action is likely due to the inhibition of δ-aminolevulinic acid synthetase, the enzyme which limits the rate of the porphyrin/heme biosynthetic pathway. The exact mechanism by which hematin produces symptomatic improvement in patients with acute episodes of the hepatic porphyrias has not been elucidated. NCATS
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Acute Kidney Injury (Phase 2)
Allografts (Phase 3)
Atherosclerosis (Phase 4)
Coproporphyria, Hereditary (Phase 2)
Diabetes Mellitus (Phase 2)
Gastroparesis (Phase 2)
Healthy Volunteers (Phase 1)
Heme Oxygenase (Decyclizing) (Phase 1)
Kidney Transplantation (Phase 3)
Myelodysplastic Syndromes (Phase 2)
Myocardial Infarction (Phase 1/Phase 2)
Myocardial Ischemia (Phase 2)
Pancreatitis (Phase 2)
Polymorphism, Genetic (Phase 1)
Porphyria, Acute Intermittent (Phase 2)
Porphyrias (Phase 2)
Porphyria, Variegate (Phase 2)
Reperfusion Injury (Phase 3)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
